



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Oxlumo (lumasiran)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
<b>Urgency:</b>					
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
<b>Medication Requested:</b>			ICD10:		
<input type="checkbox"/> Adakveo 100mg/10ml vial					
Directions for use:	Dose:	Quantity:	Duration of therapy:		
<b>Where will this medication be obtained?</b>					
<input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Other (please specify):			<input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Home Health / Home Infusion vendor <i>**Cigna's nationally preferred specialty pharmacy</i>		
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span>					
<b>Clinical Information:</b>					
<b>**This drug requires supportive documentation (chart notes, genetic test results, etc.) be attached with this request**</b>					
What is the diagnosis related to use:					
<input type="checkbox"/> Primary Hyperoxaluria Type 1 (PH1) <input type="checkbox"/> Primary Hyperoxaluria Type 2 (PH2) <input type="checkbox"/> Primary Hyperoxaluria Type 3 (PH3) <input type="checkbox"/> Post liver transplant <input type="checkbox"/> Other (please specify) _____					
Does the patient have a genetic test confirming an AGXT mutation? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
(If no or unknown) Did the patient have a liver biopsy demonstrating absent, or significantly reduced alanine glyoxylate aminotransferase (AGT) activity? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
Does the patient have a urinary oxalate level of at least 0.7mmol/24hrs/1.73 meters squared? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
(if no or unknown) Does the patient have an elevated urinary oxalate/creatinine ratio above the laboratory's age-specific normal reference range? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
Is Oxlumo being prescribed by, or in consultation with, a nephrologist, urologist, or medical geneticist? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
(if continuation of therapy) Is there a documented reduction in urinary oxalate excretion? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
(if continuation of therapy) Is there a documented reduction in the urinary oxalate/creatinine ratio? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
(if continuation of therapy) Is there a documented reduction in plasma oxalate levels from baseline? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					
(if continuation of therapy) Is there documentation of improved or stabilized clinical signs and symptoms of Primary Hyperoxaluria Type 1? (for example nephrocalcinosis, formation of renal stones, renal impairment) <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No/Unknown</span>					

**Additional pertinent information** (including prior therapy, disease stage, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at: [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v011521

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005